Background and Purpose—Clinical benefit from thrombolysis is reduced as stroke onset to
treatment time increases. The use of “mismatch” imaging to identify patients for delayed …

Background and Purpose—Clinical benefit from thrombolysis is reduced as stroke onset to
treatment time increases. The use of “mismatch” imaging to identify patients for delayed …

Introduction Evidence of the intravenous tissue plasminogen activator (tPA) efficacy beyond
the 4.5 hours window is emerging. We aim to study the factors affecting the outcome of …

The results of the pivotal intravenous tissue plasminogen activator (tPA) trials have been
reported and its use approved for acute ischemic stroke treatment for nearly 10 years [1–3] …

The mismatch between a larger perfusion lesion and smaller diffusion lesion on magnetic
resonance imaging is a validated signal of the ischemic penumbra, namely the region at risk …

Several clinical trials have demonstrated that advanced neuroimaging can select patients for
recanalization therapy in an extended time window. The favorable functional outcomes and …

To increase the percentage of acute stroke patients benefiting from thrombolysis, the utility of
expanding the time window of treatment beyond 4.5 hours after stroke onset needs to be …

OBJECTIVE: The objective of this study was to determine the proportion of stroke patients
presenting in an extended time window who have a thrombolytic treatment target …

Objective It may be possible to thrombolyse ischaemic stroke (IS) patients up to 6 h by using
penumbral imaging. We investigated whether a perfusion CT (CTP) mismatch can help to …

The rigid and narrow time-window of 3 hours for thrombolytic therapy is arguably the single
most important factor that has hampered the wider use of this therapy over the past decade …